Biogen Idec Inc (BIIB) 276.34 $BIIB
Biogen Idec (BIIB) Earnings Report: Q3 2015 Conference Call Transcript
at The Street - 1 hr 58 mins ago
The following Biogen Idec (BIIB) conference call took place on October 21, 2015, 08:30 AM ET. This is a transcript of that earnings call:
BIIB: 276.34 (+10.53)
Biogen tops Q3, will cut jobs
at Investor's Business Daily - Wed Oct 21, 5:49PM CDT
The struggling biotech announced an 11% workforce reduction and the discontinuation of some clinical programs. Those savings, in part, prompted Biogen (BIIB) to raise full-year EPS guidance by more than 70 cents to $16.20-$16.50. It also lifted...
BIIB: 276.34 (+10.53)
Watch for Biogen Idec to Potentially Pullback After Gaining 3.96% Yesterday
Comtex SmarTrend(R) - Wed Oct 21, 3:42PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $262.45 to a high of $291.01. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high of $277.29 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 276.34 (+10.53)
Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 3.96% Rise
Comtex SmarTrend(R) - Wed Oct 21, 3:42PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $262.45 to a high of $291.01. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high of $277.29 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 276.34 (+10.53)
Stocks Fall; Valeant Defends Accounting Practices
at The Street - Wed Oct 21, 2:02PM CDT
Stocks relinquish gains made earlier Wednesday as a selloff in Valeant Pharmaceuticals pressures the rest of the biotech sector.
TSLA: 210.09 (-2.94), BIIB: 276.34 (+10.53), F: 15.41 (+0.03), VRX: 118.61 (-28.13), KMB: 118.09 (+0.87), IBB: 304.46 (-1.50), TM: 123.70 (+1.49), SBUX: 60.53 (-0.35), YHOO: 31.12 (-1.71), CMG: 665.67 (-39.96), ABBV: 53.83 (-1.00), GOOGL: 671.80 (-8.20), HMC: 32.70 (+0.70), AAPL: 113.76 (-0.01), KO: 42.19 (-0.10), AMZN: 555.77 (-5.11), MU: 16.43 (-0.66), PFE: 33.46 (-0.54), LLY: 77.01 (-0.78), FCAU: 15.20 (-0.74), BMY: 62.51 (-1.38), BA: 141.19 (+2.31), WDC: 71.44 (-3.42), LRCX: 70.79 (+0.76), MCD: 102.54 (-1.30), GM: 35.42 (+1.94), KLAC: 63.98 (+10.12), RACE: 55.00 (-5.00), SNDK: 76.78 (+1.59)
Biogen Banks on High-Risk Drugs to Recapture Biotech Buzz
at The Street - Wed Oct 21, 12:46PM CDT
Biotech is a high-growth industry fueled by scientific innovation. The snapshot of Biogen Wednesday lacks the biotech buzz for which investors are willing to pay a premium.
BIIB: 276.34 (+10.53)
Biogen cutting 11 percent of its workforce
AP - Wed Oct 21, 12:39PM CDT
NEW YORK (AP) — Biogen plans to cut about 11 percent of its workforce as it refocuses its research on treatments for Alzheimer's disease and multiple sclerosis.
BIIB: 276.34 (+10.53)
Downtrend Call Working As Biogen Idec Stock Falls 8.2% (BIIB)
Comtex SmarTrend(R) - Wed Oct 21, 12:15PM CDT
SmarTrend identified a Downtrend for Biogen Idec (NASDAQ:BIIB) on September 25th, 2015 at $289.55. In approximately 4 weeks, Biogen Idec has returned 8.24% as of today's recent price of $265.68.
BIIB: 276.34 (+10.53)
Biogen To Cut 11% of Its Workforce As Part Of Restructuring Plan
Madeleine Johnson - Zacks Investment Research - Wed Oct 21, 11:31AM CDT
The biotech giant is also ending many of its drug development programs along with the workforce reduction.
WFM: 32.98 (-0.24), BIIB: 276.34 (+10.53), WMT: 58.64 (-0.11), TWTR: 29.30 (-1.61), HPQ: 28.23 (-0.33)
Here's Why Biogen (BIIB) Stock Is Climbing Today
at The Street - Wed Oct 21, 11:15AM CDT
Biogen (BIIB) stock is gaining in early afternoon trading on Wednesday, after reporting job cuts totaling 11% of its workforce and third quarter earnings results.
BIIB: 276.34 (+10.53)
Biogen Tops Q3 Earnings, Announces Job Cuts, Ups View
Arpita Dutt - Zacks Investment Research - Wed Oct 21, 10:40AM CDT
Biogen (BIIB) surpassed Q3 earnings expectations by a wide margin.
BIIB: 276.34 (+10.53), AMGN: 150.09 (-0.36), AEGR: 14.98 (-0.56)
Biogen Beats Q3 Views, Cuts Workforce, Lifts Guidance
at Investor's Business Daily - Wed Oct 21, 9:50AM CDT
Beleaguered big biotech Biogen (BIIB) beat Q3 estimates and raised guidance Wednesday morning while announcing a round of layoffs and the failure of a multiple-sclerosis drug trial. Biogen stock rose as much as 9.5% in early trading. Biogen made...
BIIB: 276.34 (+10.53)
Early Gains Fizzle, Turn Mixed; Biogen, Ferrari Rise
at Investor's Business Daily - Wed Oct 21, 9:47AM CDT
Leading indexes turned Wednesday's modest opening gains to mixed and busy action, powered primarily by quarterly reports and company news. The Nasdaq backed out of a narrow advance and slipped 0.2%. The Dow Jones industrial average and the S&P 500...
BIIB: 276.34 (+10.53), MU: 16.43 (-0.66), NTES: 137.17 (-2.03), HA: 32.87 (+1.50), DIS: 110.09 (+0.25), MANH: 70.08 (+3.89), WDC: 71.44 (-3.42), BA: 141.19 (+2.31), AOS: 68.67 (-2.12), OZRK: 47.87 (-0.67), LRCX: 70.79 (+0.76), CMG: 665.67 (-39.96), CRUS: 32.89 (+2.16), KLAC: 63.98 (+10.12), RACE: 55.00 (-5.00), SNDK: 76.78 (+1.59)
Stocks Turn Lower as Valeant Dents Biotech Sector
at The Street - Wed Oct 21, 9:41AM CDT
Stocks turn lower by mid-morning Wednesday as plummeting Valeant Pharmaceuticals shares pull the biotech sector to the downside.
BIIB: 276.34 (+10.53), TSLA: 210.09 (-2.94), VRX: 118.61 (-28.13), KMB: 118.09 (+0.87), IBB: 304.46 (-1.50), SBUX: 60.53 (-0.35), YHOO: 31.12 (-1.71), CMG: 665.67 (-39.96), ABBV: 53.83 (-1.00), GOOGL: 671.80 (-8.20), AAPL: 113.76 (-0.01), KO: 42.19 (-0.10), AMZN: 555.77 (-5.11), MU: 16.43 (-0.66), PFE: 33.46 (-0.54), FCAU: 15.20 (-0.74), BA: 141.19 (+2.31), WDC: 71.44 (-3.42), CELG: 115.92 (-0.32), GILD: 101.73 (+0.07), LRCX: 70.79 (+0.76), GM: 35.42 (+1.94), MCD: 102.54 (-1.30), KLAC: 63.98 (+10.12), RACE: 55.00 (-5.00), SNDK: 76.78 (+1.59)
Stock Market News for October 21, 2015
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 9:10AM CDT
Benchmarks ended in the red on Tuesday, dragged down by declines in biotech and healthcare stocks
BIIB: 276.34 (+10.53), HOG: 47.03 (-1.22), IBM: 140.92 (+0.28), GILD: 101.73 (+0.07), UTX: 97.97 (+2.35), PFE: 33.46 (-0.54), MRK: 50.59 (+0.20), AMGN: 150.09 (-0.36), VZ: 44.86 (-0.38), REGN: 518.53 (+3.86), TRV: 110.70 (+1.75), CELG: 115.92 (-0.32)
Biogen (BIIB) Beats on 3Q Earnings & Revenues
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 7:54AM CDT
Biogen's (BIIB) third quarter results were well above expectations with revenues also topping estimates.
BIIB: 276.34 (+10.53)
Stock Futures Rise as Boeing, GM Beat Profit Forecasts
at The Street - Wed Oct 21, 7:25AM CDT
Stock futures are higher on Wednesday after better-than-expected earnings from General Motors and Boeing.
KO: 42.19 (-0.10), AMZN: 555.77 (-5.11), BIIB: 276.34 (+10.53), TSLA: 210.09 (-2.94), KMB: 118.09 (+0.87), FCAU: 15.20 (-0.74), BA: 141.19 (+2.31), SBUX: 60.53 (-0.35), YHOO: 31.12 (-1.71), CMG: 665.67 (-39.96), GM: 35.42 (+1.94), MCD: 102.54 (-1.30), GOOGL: 671.80 (-8.20), AAPL: 113.76 (-0.01)
Biogen to Cut 11% of Workforce, Multiple Sclerosis Drugs Sales Improve
at The Street - Wed Oct 21, 7:00AM CDT
The company raised earnings and revenue guidance modestly for the remainder of the year due to the cost savings from the restructuring.
BIIB: 276.34 (+10.53)
Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS
Business Wire - Wed Oct 21, 6:31AM CDT
The Phase 3 ASCEND study investigating natalizumab in the treatment of secondary progressive multiple sclerosis (SPMS) did not achieve its primary and secondary endpoints, Biogen (NASDAQ: BIIB) reported today. During the study, natalizumab was generally well tolerated and adverse events were consistent with its known safety profile.
BIIB: 276.34 (+10.53)
Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance
Business Wire - Wed Oct 21, 6:30AM CDT
--First patient enrolled in aducanumab Phase 3 studies for Alzheimer's disease
BIIB: 276.34 (+10.53)
Biogen Idec (BIIB) Earnings Report: Q3 2015 Conference Call Transcript
at The Street - 1 hr 58 mins ago
The following Biogen Idec (BIIB) conference call took place on October 21, 2015, 08:30 AM ET. This is a transcript of that earnings call:
BIIB: 276.34 (+10.53)
Biogen tops Q3, will cut jobs
at Investor's Business Daily - Wed Oct 21, 5:49PM CDT
The struggling biotech announced an 11% workforce reduction and the discontinuation of some clinical programs. Those savings, in part, prompted Biogen (BIIB) to raise full-year EPS guidance by more than 70 cents to $16.20-$16.50. It also lifted...
BIIB: 276.34 (+10.53)
Watch for Biogen Idec to Potentially Pullback After Gaining 3.96% Yesterday
Comtex SmarTrend(R) - Wed Oct 21, 3:42PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $262.45 to a high of $291.01. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high of $277.29 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 276.34 (+10.53)
Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 3.96% Rise
Comtex SmarTrend(R) - Wed Oct 21, 3:42PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $262.45 to a high of $291.01. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high of $277.29 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 276.34 (+10.53)
Stocks Fall; Valeant Defends Accounting Practices
at The Street - Wed Oct 21, 2:02PM CDT
Stocks relinquish gains made earlier Wednesday as a selloff in Valeant Pharmaceuticals pressures the rest of the biotech sector.
TSLA: 210.09 (-2.94), BIIB: 276.34 (+10.53), F: 15.41 (+0.03), VRX: 118.61 (-28.13), KMB: 118.09 (+0.87), IBB: 304.46 (-1.50), TM: 123.70 (+1.49), SBUX: 60.53 (-0.35), YHOO: 31.12 (-1.71), CMG: 665.67 (-39.96), ABBV: 53.83 (-1.00), GOOGL: 671.80 (-8.20), HMC: 32.70 (+0.70), AAPL: 113.76 (-0.01), KO: 42.19 (-0.10), AMZN: 555.77 (-5.11), MU: 16.43 (-0.66), PFE: 33.46 (-0.54), LLY: 77.01 (-0.78), FCAU: 15.20 (-0.74), BMY: 62.51 (-1.38), BA: 141.19 (+2.31), WDC: 71.44 (-3.42), LRCX: 70.79 (+0.76), MCD: 102.54 (-1.30), GM: 35.42 (+1.94), KLAC: 63.98 (+10.12), RACE: 55.00 (-5.00), SNDK: 76.78 (+1.59)
Biogen Banks on High-Risk Drugs to Recapture Biotech Buzz
at The Street - Wed Oct 21, 12:46PM CDT
Biotech is a high-growth industry fueled by scientific innovation. The snapshot of Biogen Wednesday lacks the biotech buzz for which investors are willing to pay a premium.
BIIB: 276.34 (+10.53)
Biogen cutting 11 percent of its workforce
AP - Wed Oct 21, 12:39PM CDT
NEW YORK (AP) — Biogen plans to cut about 11 percent of its workforce as it refocuses its research on treatments for Alzheimer's disease and multiple sclerosis.
BIIB: 276.34 (+10.53)
Downtrend Call Working As Biogen Idec Stock Falls 8.2% (BIIB)
Comtex SmarTrend(R) - Wed Oct 21, 12:15PM CDT
SmarTrend identified a Downtrend for Biogen Idec (NASDAQ:BIIB) on September 25th, 2015 at $289.55. In approximately 4 weeks, Biogen Idec has returned 8.24% as of today's recent price of $265.68.
BIIB: 276.34 (+10.53)
Biogen To Cut 11% of Its Workforce As Part Of Restructuring Plan
Madeleine Johnson - Zacks Investment Research - Wed Oct 21, 11:31AM CDT
The biotech giant is also ending many of its drug development programs along with the workforce reduction.
WFM: 32.98 (-0.24), BIIB: 276.34 (+10.53), WMT: 58.64 (-0.11), TWTR: 29.30 (-1.61), HPQ: 28.23 (-0.33)
Here's Why Biogen (BIIB) Stock Is Climbing Today
at The Street - Wed Oct 21, 11:15AM CDT
Biogen (BIIB) stock is gaining in early afternoon trading on Wednesday, after reporting job cuts totaling 11% of its workforce and third quarter earnings results.
BIIB: 276.34 (+10.53)
Biogen Tops Q3 Earnings, Announces Job Cuts, Ups View
Arpita Dutt - Zacks Investment Research - Wed Oct 21, 10:40AM CDT
Biogen (BIIB) surpassed Q3 earnings expectations by a wide margin.
BIIB: 276.34 (+10.53), AMGN: 150.09 (-0.36), AEGR: 14.98 (-0.56)
Biogen Beats Q3 Views, Cuts Workforce, Lifts Guidance
at Investor's Business Daily - Wed Oct 21, 9:50AM CDT
Beleaguered big biotech Biogen (BIIB) beat Q3 estimates and raised guidance Wednesday morning while announcing a round of layoffs and the failure of a multiple-sclerosis drug trial. Biogen stock rose as much as 9.5% in early trading. Biogen made...
BIIB: 276.34 (+10.53)
Early Gains Fizzle, Turn Mixed; Biogen, Ferrari Rise
at Investor's Business Daily - Wed Oct 21, 9:47AM CDT
Leading indexes turned Wednesday's modest opening gains to mixed and busy action, powered primarily by quarterly reports and company news. The Nasdaq backed out of a narrow advance and slipped 0.2%. The Dow Jones industrial average and the S&P 500...
BIIB: 276.34 (+10.53), MU: 16.43 (-0.66), NTES: 137.17 (-2.03), HA: 32.87 (+1.50), DIS: 110.09 (+0.25), MANH: 70.08 (+3.89), WDC: 71.44 (-3.42), BA: 141.19 (+2.31), AOS: 68.67 (-2.12), OZRK: 47.87 (-0.67), LRCX: 70.79 (+0.76), CMG: 665.67 (-39.96), CRUS: 32.89 (+2.16), KLAC: 63.98 (+10.12), RACE: 55.00 (-5.00), SNDK: 76.78 (+1.59)
Stocks Turn Lower as Valeant Dents Biotech Sector
at The Street - Wed Oct 21, 9:41AM CDT
Stocks turn lower by mid-morning Wednesday as plummeting Valeant Pharmaceuticals shares pull the biotech sector to the downside.
BIIB: 276.34 (+10.53), TSLA: 210.09 (-2.94), VRX: 118.61 (-28.13), KMB: 118.09 (+0.87), IBB: 304.46 (-1.50), SBUX: 60.53 (-0.35), YHOO: 31.12 (-1.71), CMG: 665.67 (-39.96), ABBV: 53.83 (-1.00), GOOGL: 671.80 (-8.20), AAPL: 113.76 (-0.01), KO: 42.19 (-0.10), AMZN: 555.77 (-5.11), MU: 16.43 (-0.66), PFE: 33.46 (-0.54), FCAU: 15.20 (-0.74), BA: 141.19 (+2.31), WDC: 71.44 (-3.42), CELG: 115.92 (-0.32), GILD: 101.73 (+0.07), LRCX: 70.79 (+0.76), GM: 35.42 (+1.94), MCD: 102.54 (-1.30), KLAC: 63.98 (+10.12), RACE: 55.00 (-5.00), SNDK: 76.78 (+1.59)
Stock Market News for October 21, 2015
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 9:10AM CDT
Benchmarks ended in the red on Tuesday, dragged down by declines in biotech and healthcare stocks
BIIB: 276.34 (+10.53), HOG: 47.03 (-1.22), IBM: 140.92 (+0.28), GILD: 101.73 (+0.07), UTX: 97.97 (+2.35), PFE: 33.46 (-0.54), MRK: 50.59 (+0.20), AMGN: 150.09 (-0.36), VZ: 44.86 (-0.38), REGN: 518.53 (+3.86), TRV: 110.70 (+1.75), CELG: 115.92 (-0.32)
Biogen (BIIB) Beats on 3Q Earnings & Revenues
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 7:54AM CDT
Biogen's (BIIB) third quarter results were well above expectations with revenues also topping estimates.
BIIB: 276.34 (+10.53)
Stock Futures Rise as Boeing, GM Beat Profit Forecasts
at The Street - Wed Oct 21, 7:25AM CDT
Stock futures are higher on Wednesday after better-than-expected earnings from General Motors and Boeing.
KO: 42.19 (-0.10), AMZN: 555.77 (-5.11), BIIB: 276.34 (+10.53), TSLA: 210.09 (-2.94), KMB: 118.09 (+0.87), FCAU: 15.20 (-0.74), BA: 141.19 (+2.31), SBUX: 60.53 (-0.35), YHOO: 31.12 (-1.71), CMG: 665.67 (-39.96), GM: 35.42 (+1.94), MCD: 102.54 (-1.30), GOOGL: 671.80 (-8.20), AAPL: 113.76 (-0.01)
Biogen to Cut 11% of Workforce, Multiple Sclerosis Drugs Sales Improve
at The Street - Wed Oct 21, 7:00AM CDT
The company raised earnings and revenue guidance modestly for the remainder of the year due to the cost savings from the restructuring.
BIIB: 276.34 (+10.53)
Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS
Business Wire - Wed Oct 21, 6:31AM CDT
The Phase 3 ASCEND study investigating natalizumab in the treatment of secondary progressive multiple sclerosis (SPMS) did not achieve its primary and secondary endpoints, Biogen (NASDAQ: BIIB) reported today. During the study, natalizumab was generally well tolerated and adverse events were consistent with its known safety profile.
BIIB: 276.34 (+10.53)
Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance
Business Wire - Wed Oct 21, 6:30AM CDT
--First patient enrolled in aducanumab Phase 3 studies for Alzheimer's disease
BIIB: 276.34 (+10.53)
